Journal of thoracic disease最新文献

{"title":"Technological advances in single-use or disposable bronchoscopy: an evaluation of the Innovative Ambu^® aScope™ 5 in a quaternary referral bronchoscopy unit.","authors":"Noreen Tangney, Emily O'Reilly, Mairead O'Donnell, Anne O'Mahony, Kevin Deasy, Hisham Ibrahim, Andre Pozza, Marcus Peter Kennedy","doi":"10.21037/jtd-24-1538","DOIUrl":"10.21037/jtd-24-1538","url":null,"abstract":"<p><strong>Background: </strong>Single-use flexible bronchoscopes (SUFBs) offer various advantages over reusable bronchoscopes (RBs) including portability and cost-effectiveness, and potentially reduced infection transmission. Our study aimed to review the performance of the Ambu^® aScope™ 5 Broncho suite in Cork University Hospital.</p><p><strong>Methods: </strong>Following ethical approval, data was collected prospectively on procedures performed with the Ambu^® aScope™ 5 in Cork University Hospital. Data included patient demographics, procedure details (location, indication, SUFB size, procedures, complications), and user satisfaction and demographics.</p><p><strong>Results: </strong>There were 98 procedures performed with the Ambu^® aScope™ 5, all in the endoscopy suite. There were 42 female patients (42.9%) and 56 male (57.1%). Various sized models were used-2.7/1.2 (n=3), 4.2/2.2 (n=4), 5/2.2 (n=60), 5.6/2.8 (n=31). Infection was the most common indication while others included malignancy, haemoptysis, sarcoidosis, and asthma. The most commonly performed procedure was airway inspection (n=98), while bronchoalveolar lavage (BAL) (n=84), brushings (n=3), endobronchial biopsies (n=5), transbronchial needle aspiration (TBNA) (n=1), and argon plasma coagulation (APC) (n=1) were among others. The average user satisfaction rating (from one to five in ascending order of satisfaction) was 4.8 [5 (n=85), 4 (n=9), 3 (n=1), 2 (n=3), 1 (n=0)]. The most common reason for user dissatisfaction was related to suction (n=3). Conversion from single-use to RB was not required in any case. There were no bronchoscope-related patient complications.</p><p><strong>Conclusions: </strong>Within this cohort of patients, the Ambu^® aScope™ 5 was both safe and versatile with a high level of user satisfaction.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"17 1","pages":"42-50"},"PeriodicalIF":2.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative day 1 discharge for segmentectomy using a minimally invasive approach after drain removal on the day of surgery.","authors":"Hitoshi Igai, Akinobu Ida, Kazuki Numajiri, Kazuhito Nii, Mitsuhiro Kamiyoshihara","doi":"10.21037/jtd-24-1372","DOIUrl":"10.21037/jtd-24-1372","url":null,"abstract":"<p><strong>Background: </strong>Although early removal of postoperative chest drains in segmentectomy may be difficult due to the management of air leakage in intersegmental planes, patients can be discharged earlier if it is successfully achieved. In segmentectomy, we evaluated the feasibility of postoperative day (POD) 1 discharge using a minimally invasive approach (MIA) after drain removal on the day of surgery (DOS).</p><p><strong>Methods: </strong>Ninety patients who underwent segmentectomy via MIA between July 2021 and September 2023 were included in this retrospective study. These patients were divided into those who received drain removal on DOS or after DOS. Clinical characteristics and perioperative outcomes were compared between the two groups. In addition, the factors associated with drain removal on DOS and discharge on POD1 in the patients who received drain removal on DOS were identified.</p><p><strong>Results: </strong>Drains were removed on DOS in 67 patients (74.4%). Therefore, the 90 patients were divided into those who underwent drain removal on DOS (n=67) or after DOS (n=23). Patients who underwent drain removal on DOS had significantly higher forced expiratory volume in 1 second (FEV1.0) % (P=0.03) and shorter postoperative hospital stay (P<0.001). In multivariate analyses, FEV1.0% was significantly associated with drain removal on DOS (odds ratio: 0.934, 95% confidence interval: 0.880-0.993, P=0.03). Of the 67 patients who underwent drain removal on DOS, 31 (46.3%) were discharged on POD1. Among the variables, surgery performed by the chief surgeon was significantly associated with discharge on POD1 (<i>vs</i>. others, odds ratio: 0.117, 95% confidence interval: 0.019-0.730, P=0.02).</p><p><strong>Conclusions: </strong>POD1 discharge for segmentectomy using a MIA after drain removal on DOS is considered feasible. However, we still have room for improvement as 53.7% of patients were discharged on POD2 or later despite drain removal on DOS.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"17 1","pages":"82-92"},"PeriodicalIF":2.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association of ventilator mechanical power with weaning outcomes in intensive care unit patients: a narrative review.","authors":"Jacob Harder, Joshua Molter, Kenneth Nugent","doi":"10.21037/jtd-24-1381","DOIUrl":"10.21037/jtd-24-1381","url":null,"abstract":"<p><strong>Background and objective: </strong>Mechanical power (MP) provides an integrated index of the mechanical properties of the respiratory system during mechanical ventilation. Increased levels of MP may identify patients who will do poorly during weaning and extubation. This literature review investigated the use of MP as a predictor of weaning outcomes in intensive care unit (ICU) patients, including a focused comparison of patients with coronavirus disease 19 (COVID-19) infections and patients with other causes of respiratory failure.</p><p><strong>Methods: </strong>A review of the literature using PubMed, Embase, MEDLINE, and Preprint identified 305 possible studies; after removal of duplicates, 219 studies were screened, and five papers were selected for analysis. A search updated in 2024 identified four additional papers to include in this review.</p><p><strong>Key content and findings: </strong>These studies demonstrate that higher MP levels are associated with weaning failure in ICU patients and that adjustment of MP for lung-thorax compliance (LTC) improves the prediction of outcomes. One study analyzed outcomes in patients with COVID-19 infections and reported that despite having higher MPs, patients with COVID-19 had lower rates of weaning failures. This result suggests different respiratory mechanics in these patients that could complicate weaning decisions.</p><p><strong>Conclusions: </strong>In summary, MP can predict weaning outcomes in patients with respiratory failure requiring mechanical ventilation. However, some patients with COVID-19 infection may have unusual respiratory mechanics that may influence these associations.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"17 1","pages":"487-495"},"PeriodicalIF":2.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Camrelizumab combined with neoadjuvant docetaxel, oxaliplatin, and S1 as induction therapy for locally advanced esophageal squamous cell cancer: a real-world single-center cohort study.","authors":"Guanghui Xu, Shushang Liu, Shu Wang, Jiyang Zheng, Yuhao Wang, Haoyuan Wang, Sarbajit Mukherjee, Jianjun Yang","doi":"10.21037/jtd-2024-2248","DOIUrl":"10.21037/jtd-2024-2248","url":null,"abstract":"<p><strong>Background: </strong>Camrelizumab combined with chemotherapy has shown significant clinical benefits in the first-line treatment of advanced esophageal squamous cell cancer (ESCC). Despite promising results from randomized trials, there is a need for real-world evidence to understand the broader applicability and long-term outcomes of neoadjuvant treatments in diverse patient populations with ESCC. This study aimed to evaluate the efficacy and safety of neoadjuvant camrelizumab combined with chemotherapy in patients with resectable locally advanced ESCC in a real-world setting.</p><p><strong>Methods: </strong>We retrospectively reviewed clinical data from 83 patients with locally advanced, potentially resectable ESCC who received neoadjuvant camrelizumab combined with docetaxel, oxaliplatin, and S1 chemotherapy at Xijing Hospital of Digestive Diseases, Fourth Military Medical University from March 2020 to May 2023. Inclusion criteria were based on clinical stage, histological confirmation, and patient tolerance. Baseline clinical characteristics were assessed using standard diagnostic tools. Treatment involved three cycles of camrelizumab combined with chemotherapy, with efficacy and safety evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Tumor downstaging, survival outcomes, and safety were assessed.</p><p><strong>Results: </strong>The median age of patients was 61 years (range, 46-75 years), and tumors were predominantly located in the middle (n=49, 59.04%) and lower (n=23, 27.71%) regions of the esophagus. Most patients were diagnosed at stages III-IV (55.42% and 38.55%, respectively), and all of the patients completed neoadjuvant treatment. Additionally, 24 (28.92%) patients achieved complete response (CR), 40 (48.19%) patients achieved partial response (PR), and 9 (10.84%) patients achieved stable disease (SD). The objective response rate (ORR) was 77.11% (64/83), and the disease control rate (DCR) was 87.95% (73/83). Of the 14 patients who underwent surgery, the R0 resection rate was 100%, and 28.57% (4/14) achieved pathological CR (pCR). The median follow-up time was 31.0 months, and the 3-year overall survival (OS) rate was 56.9%. The incidence of grade ≥3 adverse events was 6.02% (5/83). No deaths occurred.</p><p><strong>Conclusions: </strong>While our real-world data suggest potential benefits of neoadjuvant camrelizumab plus chemotherapy in locally advanced ESCC, the absence of a control group limits the generalizability of these findings. Further randomized studies are needed to validate these results.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"17 1","pages":"441-449"},"PeriodicalIF":2.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving diagnostic capabilities in lung cancer through next-generation sequencing: a narrative review.","authors":"Andrew Figueroa, Shadi Safar Gholi, Girish Jayant, Raj Wadgaonkar, Ahmed Gubran, Stephen J Kuperberg","doi":"10.21037/jtd-24-488","DOIUrl":"10.21037/jtd-24-488","url":null,"abstract":"<p><strong>Background and objective: </strong>Lung neoplasia is the leading cause of cancer death worldwide, thus, early detection and accuracy in establishing a diagnosis is paramount. As a consequence of decades of basic and translational studies revealing the genetic basis of lung cancer, a paradigm shift has occurred toward a personalized approach to medicine whereby mutational analysis confers an opportunity for safer, and expedient treatment options. In this context, next-generation sequencing (NGS) has emerged as a vital technological advance, and has become increasingly established as a core method for rapidly and effectively identifying actionable mutations in lung cancer. For these reasons, an updated review of the literature across invasive and non-invasive diagnostic modalities in lung cancer is warranted to inform diagnostic approaches and prompt new investigations. The objective of the present review is to provide a focused update on applications of NGS in lung cancer diagnostics, with a special focus on tissue acquisition methodologies and mutational analysis.</p><p><strong>Methods: </strong>The search strategy included a survey of the current literature from 2005 to 2024 in PubMed, Medline, Scopus, and Google Scholar. Eligible study types included original research, literature reviews (narrative and systematic), and observational studies. which encompassed findings pertinent to the lung cancer diagnostics, mutational analysis and lung cancer treatment overlapping with applications and use of NGS technologies.</p><p><strong>Key content and findings: </strong>There are extensive and diverse advantages to the use of NGS in lung cancer diagnostics, especially when compared to traditional sequencing techniques including, speed, effectiveness, easy adoption in the context of analysis of samples prepared for lung cancer diagnosis. Advances in cell-free DNA reinforce the firm role of NGS in novel approaches.</p><p><strong>Conclusions: </strong>NGS implementation is a crucial and beneficial technological leap in lung cancer diagnosis, especially given the environment of novel and established targeted and immune based therapies which require mutational testing. Its numerous benefits such as expedient results and reduced sample requirements will continue to ability optimize lung cancer outcomes by virtue of improved patient safety, reduction of unnecessary procedures, and provision of accurate results.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"17 1","pages":"476-486"},"PeriodicalIF":2.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Sanfeng Tongqiao Diwan in treating upper airway cough syndrome: issues & insights.","authors":"Shuyi Chen, Fei He","doi":"10.21037/jtd-2024-1938","DOIUrl":"10.21037/jtd-2024-1938","url":null,"abstract":"","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"17 1","pages":"514-515"},"PeriodicalIF":2.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The diagnostic value of vascular architecture in solid solitary pulmonary nodules quantified by dynamic contrast enhanced MRI.","authors":"Liang Fu, Xiaoyu Pan, Haiming Ding, Ying Qin, Wanyun Huang, Shunzu Lu, Kai Li, Liling Long","doi":"10.21037/jtd-24-1467","DOIUrl":"10.21037/jtd-24-1467","url":null,"abstract":"<p><strong>Background: </strong>Alterations in the vascular microenvironment of cancer have gradually gained widespread attention in oncology research, and early qualitative diagnosis using noninvasive examination techniques is crucial in clinical practice. This study aimed to explore the value of quantitative parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in the assessment of vascular architecture of solid solitary pulmonary nodules (SSPNs).</p><p><strong>Methods: </strong>DCE-MRI scan images of a total of 79 patients with SSPNs from November 2021 to December 2023 were prospectively analyzed. Quantitative permeability parameters K^trans, K_ep, and V_e values of the lesions were measured, labeled immunohistochemically with CD31 microvessel density (CD31-MVD), smooth muscle actin microvessel density (SMA-MVD), and vascular endothelial growth factor (VEGF), and quantitative values of vascular architectural parameters were obtained using the image analysis software Image-J. The diagnostic efficacy of quantitative permeability parameters for the diagnosis of malignant SSPNs was analyzed by receiver operating characteristic (ROC) curves using surgical pathology findings as the gold standard for the diagnosis of malignant SSPNs. Spearman's correlation analysis was used to evaluate the relationship between quantitative permeability parameters and vascular construct parameters.</p><p><strong>Results: </strong>The study included 51 female patients (64.6%) with a mean age of 50.5±11.5 years. Only 21 patients (26.6%) had a smoking history, and 30 patients (38.0%) had a normal weight. Statistically significant differences were found between benign and malignant SSPNs subgroups in K^trans and V_e values in quantitative permeability parameters, and in SMA-MVD and microvascular perfusion index (MPI) in vascular conformation parameters (P<0.05). K^trans and V_e values showed high diagnostic value for malignant SSPNs [area under the curve (AUC), 0.813 and 0.759]. K^trans, K_ep, and V_e were significantly positively correlated with CD31-MVD, with r-values of 0.857, 0.830, and 0.798 (P<0.05); they were also significantly positively correlated with VEGF, with r-values of 0.851, 0.859, and 0.764 (P<0.05); and K_trans and K_ep were significantly negatively correlated with MPI, with r-values were -0.779 and -0.864 (P<0.05).</p><p><strong>Conclusions: </strong>The quantitative permeability parameters of DCE-MRI correlate with some of the vascular architectural parameters, and magnetic resonance image-based quantification of pulmonary nodal vascular architecture provides a noninvasive method for the differential diagnosis of SSPNs.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"17 1","pages":"19-30"},"PeriodicalIF":2.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic sites, prognosis, and a new nomogram for predicting overall survival among small cell lung cancer patients with liver metastasis: a retrospective study based on SEER.","authors":"Rixin Li, Hui Li, Chenchen Tang, Heran Cui, Rui Zhong, Yan Liu, Jingjing Liu","doi":"10.21037/jtd-24-1423","DOIUrl":"10.21037/jtd-24-1423","url":null,"abstract":"<p><strong>Background: </strong>Small cell lung cancer (SCLC) is acknowledged as the most aggressive histological subtype among the various types of lung cancer. Among patients with advanced-stage SCLC, liver metastasis (LM) is frequently observed and is associated with the most unfavorable prognosis. The purpose of the present study is to investigate the synchronous metastatic sites in SCLC patients with LM, and to construct a nomogram for predicting the survival of these patients.</p><p><strong>Methods: </strong>The data of SCLC patients with LM in the Surveillance, Epidemiology, and End Results (SEER) database were retrospectively analyzed. Univariate and multivariate Cox analyses were conducted to identify independent prognostic factors. A prognostic nomogram was developed and validated through calibration curves, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA). There were 128 patients from the Jilin Cancer Hospital selected for external validation. The overall survival (OS) of patients with LM was estimated using the Kaplan-Meier method, and survival differences were compared using the log-rank test.</p><p><strong>Results: </strong>This study included a total of 8,858 patients, with independent prognostic factors for LM in SCLC patients being age, gender, primary site, surgery, radiotherapy, chemotherapy, brain metastasis, and lung metastasis. The calibration, ROC curves, and DCA collectively demonstrated the outstanding predictive accuracy of the prognostic nomogram. Bone was the most common accompanying organ for metastasis in SCLC-LM patients, followed by the lungs. Among the eight different groups based on metastatic patterns, compared to patients with isolated LM, those with concurrent metastases at other sites had a higher risk of death and poorer prognosis. Patients with LM accompanied by lung metastasis had the poorest prognosis, with a median survival time of 2 months.</p><p><strong>Conclusions: </strong>The nomogram is anticipated to serve as a precise and individualized instrument for forecasting the survival of SCLC with LM. Identifying the locations of synchronous extra LM and their corresponding prognoses can aid in guiding treatment decisions and optimizing treatment approaches.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"17 1","pages":"344-356"},"PeriodicalIF":2.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Could combination immunotherapy give light to resectable esophageal squamous cell carcinoma?","authors":"Kazuhiro Shiraishi, Shun Yamamoto, Hiroshi Imazeki, Ken Kato","doi":"10.21037/jtd-24-1535","DOIUrl":"10.21037/jtd-24-1535","url":null,"abstract":"","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"17 1","pages":"15-18"},"PeriodicalIF":2.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of the PD-1 inhibitor penpulimab in combination with chemotherapy for advanced lung squamous cell carcinoma: insights from a phase III multicenter study.","authors":"Fumihiro Yamaguchi, Chika Kondo, Kento Hirata, Kenta Miyo, Mamiko Kanzaki, Kazusawa Tei, Hitoshi Kobayashi","doi":"10.21037/jtd-24-1547","DOIUrl":"10.21037/jtd-24-1547","url":null,"abstract":"","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"17 1","pages":"10-14"},"PeriodicalIF":2.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}